Clinical Research Advances in Weekly Paclitaxel Administration for Metastatic Breast Cancer

伍长娟,陈礼明,唐丽琴,吴恒

DOI: https://doi.org/10.3969/j.issn.1009-6469.2009.04.004

2009-01-01

Abstract:Paclitaxel has significant clinical activity in many cancers,especially metastatic breast cancer.Currently,the commonly used dose schedule for paclitaxel is standard every-3-week administration(175 mg·m-2 for paclitaxel as a 3-hour i.v.infusion every 3 weeks).For the past few years,a number of clinical trials have evaluated the tolerability and efficacy of weekly paclitaxel administration.Studies indicate that weekly infusion of paclitaxel for an 1 h infusion was not less active than every-3-week administration,and generally well tolerated in patients with metastatic breast cancer.This schedule could also improve the benefit-to-risk ratio.Weekly paclitaxel is a feasible,safe,and active therapy for metastatic breast cancer.